{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T02:59:59Z","timestamp":1785380399697,"version":"3.55.0"},"reference-count":157,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chongqing Science and Health Joint Medical Research Project","award":["2023GDRC010"],"award-info":[{"award-number":["2023GDRC010"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Natural killer\/T-cell lymphoma (NKTCL) is a rare and aggressive Epstein\u2013Barr virus (EBV)-associated lymphoma characterized by intrinsic chemoresistance and an immunosuppressive tumor immune microenvironment (TIME). EBV-driven immune dysregulation provides a biological rationale for immunotherapy. This review summarizes current advances in immunotherapeutic strategies for NKTCL, integrating molecular mechanisms, clinical evidence, and resistance mechanisms within the context of TIME remodeling and immune reprogramming. We synthesize evidence from clinical trials, translational studies, and preclinical investigations evaluating immune checkpoint inhibitors, antibody-based therapies, adoptive cellular therapies, immune engagers, EBV-directed immunotherapies, and multimodal combination strategies in NKTCL. Among these strategies, PD-1\/PD-L1 inhibitors are the most extensively studied immunotherapies in NKTCL and demonstrate clinically meaningful activity across different clinical settings. However, therapeutic responses remain heterogeneous, and primary or acquired resistance is common, driven by EBV-associated immune suppression, defective antigen presentation, metabolic reprogramming, and multi-checkpoint co-expression. Beyond immune checkpoint blockade, emerging approaches\u2014including dual-checkpoint inhibition, epigenetic and metabolic combinations, antibody\u2013drug conjugates, EBV-specific cytotoxic T lymphocytes, chimeric antigen receptor (CAR)-based platforms, immune engagers, and EBV vaccines\u2014have shown encouraging signals in early-phase studies. Increasing evidence also supports multimodal strategies integrating immunotherapy with radiotherapy and other immune-modulatory interventions to enhance immune reprogramming and improve response durability. Overall, immunotherapy has substantially expanded the therapeutic landscape of NKTCL but remains constrained by complex EBV\u2013TIME interactions and interpatient heterogeneity. Future progress will rely on biologically informed patient stratification, rational multimodal combination strategies, and integration of innovative immune platforms to establish a durable, immune-reprogramming-centered treatment paradigm for EBV-driven NKTCL.<\/jats:p>","DOI":"10.3390\/cancers18091358","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T12:29:11Z","timestamp":1777033751000},"page":"1358","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy in NK\/T-Cell Lymphoma: Mechanisms, Clinical Evidence, Resistance, and Emerging Multimodal Strategies"],"prefix":"10.3390","volume":"18","author":[{"given":"Qihao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4008-3060","authenticated-orcid":false,"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-017-0452-9","article-title":"The Diagnosis and Management of NK\/T-Cell Lymphomas","volume":"10","author":"Tse","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13045-022-01293-5","article-title":"How We Treat NK\/T-Cell Lymphomas","volume":"15","author":"Tse","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1","article-title":"Frequent Expression of P-Glycoprotein\/MDR1 by Nasal T-Cell Lymphoma Cells","volume":"76","author":"Yamaguchi","year":"1995","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/ajh.21256","article-title":"Immunohistochemical Expression and Clinical Significance of P-Glycoprotein in Previously Untreated Extranodal NK\/T-Cell Lymphoma, Nasal Type","volume":"83","author":"Wang","year":"2008","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1349-7006.2008.00768.x","article-title":"Phase I Study of Dexamethasone, Methotrexate, Ifosfamide, L-asparaginase, and Etoposide (SMILE) Chemotherapy for Advanced-stage, Relapsed or Refractory Extranodal Natural Killer (NK)\/T-cell Lymphoma and Leukemia","volume":"99","author":"Yamaguchi","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)\/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for Natural Killer\/T-Cell Lymphoma: Analysis of Safety and Efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","article-title":"Efficacy of L-Asparaginase with Methotrexate and Dexamethasone (AspaMetDex Regimen) in Patients with Refractory or Relapsing Extranodal NK\/T-Cell Lymphoma, a Phase 2 Study","volume":"117","author":"Jaccard","year":"2011","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood.V118.21.2688.2688","article-title":"Modified SMILE in the Treatment of Natural Killer T-Cell Lymphoma, Nasal and Nasal Type: A Single Center US Experience","volume":"118","author":"Lunning","year":"2011","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/ajh.26335","article-title":"Sequential P-GEMOX and Radiotherapy for Early-stage Extranodal Natural Killer\/T-cell Lymphoma: A Multicenter Study","volume":"96","author":"Zhang","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"58396","DOI":"10.18632\/oncotarget.11135","article-title":"The DDGP (Cisplatin, Dexamethasone, Gemcitabine, and Pegaspargase) Regimen for Treatment of Extranodal Natural Killer (NK)\/T-Cell Lymphoma, Nasal Type","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"D1671","DOI":"10.1093\/nar\/gkae973","article-title":"Generic Diagramming Platform (GDP): A Comprehensive Database of High-Quality Biomedical Graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","article-title":"PD-L1 Is Upregulated by EBV-Driven LMP1 through NF-\u03baB Pathway and Correlates with Poor Prognosis in Natural Killer\/T-Cell Lymphoma","volume":"9","author":"Bi","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wang, L., and Ning, S. (2021). New Look of EBV LMP1 Signaling Landscape. Cancers, 13.","DOI":"10.3390\/cancers13215451"},{"key":"ref_15","first-page":"119","article-title":"The Latent Membrane Protein 1 (LMP1)","volume":"391","author":"Kieser","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","article-title":"Oncogenic Activation of the STAT3 Pathway Drives PD-L1 Expression in Natural Killer\/T-Cell Lymphoma","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1600-065X.2008.00706.x","article-title":"Interleukin-10: New Perspectives on an Old Cytokine","volume":"226","author":"Mosser","year":"2008","journal-title":"Immunol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1128\/JVI.77.7.4139-4148.2003","article-title":"A Positive Autoregulatory Loop of LMP1 Expression and STAT Activation in Epithelial Cells Latently Infected with Epstein-Barr Virus","volume":"77","author":"Chen","year":"2003","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-025-01313-w","article-title":"Early Growth Response 1 as a Key Regulator of PD-L1 Expression and Immune Evasion in Extranodal NK\/T-Cell Lymphoma","volume":"15","author":"Lee","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.2147\/OTT.S187280","article-title":"Anti-PD1 up-Regulates PD-L1 Expression and Inhibits T-Cell Lymphoma Progression: Possible Involvement of an IFN-\u03b3-Associated JAK-STAT Pathway","volume":"12","author":"Xue","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/s40001-025-02694-1","article-title":"The PD-1\/PD-L1 Pathway and Epstein\u2013Barr Virus","volume":"30","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrc1452","article-title":"Epstein\u2013Barr Virus: 40 Years On","volume":"4","author":"Young","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1158\/1078-0432.CCR-11-2395","article-title":"Expression of Epstein-Barr Virus-Encoded Proteins in Extranodal NK\/T-Cell Lymphoma, Nasal Type (ENKL): Differences in Biologic and Clinical Behaviors of LMP1-Positive and -Negative ENKL","volume":"18","author":"Kanemitsu","year":"2012","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1054\/bjoc.2000.1687","article-title":"The Latency Pattern of Epstein-Barr Virus Infection and Viral IL-10 Expression in Cutaneous Natural Killer\/T-Cell Lymphomas","volume":"84","author":"Xu","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41375-018-0324-5","article-title":"Genomic and Transcriptomic Landscapes of Epstein-Barr Virus in Extranodal Natural Killer T-Cell Lymphoma","volume":"33","author":"Peng","year":"2019","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41564-018-0334-0","article-title":"Defective Epstein-Barr Virus in Chronic Active Infection and Haematological Malignancy","volume":"4","author":"Okuno","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1158\/0008-5472.CAN-24-0132","article-title":"Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK\/T-Cell Lymphoma","volume":"84","author":"Ito","year":"2024","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Kou, H., Cheng, Z., Lu, X., Hu, Y., and Tang, L.V. (2025). P3-GemOx as a Novel Immunochemotherapy Candidate in NK\/T-Cell Lymphoma Management. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1666601"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/ajh.26922","article-title":"A Phase II Study of Sintilimab, Anlotinib, and Pegaspargase Sandwiched with Radiotherapy as First-Line Therapy in Patients with Newly Diagnosed, Stage I-II Extranodal Natural-Killer\/T-Cell Lymphoma","volume":"98","author":"Sun","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1016\/S2352-3026(24)00066-8","article-title":"First-Line Sintilimab with Pegaspargase, Gemcitabine, and Oxaliplatin in Advanced Extranodal Natural Killer\/T Cell Lymphoma (SPIRIT): A Multicentre, Single-Arm, Phase 2 Trial","volume":"11","author":"Tian","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-024-01782-8","article-title":"Anti-Metabolic Agent Pegaspargase plus PD-1 Antibody Sintilimab for First-Line Treatment in Advanced Natural Killer T Cell Lymphoma","volume":"9","author":"Xiong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41392-020-00331-3","article-title":"Combination of Anti-PD-1 Antibody with P-GEMOX as a Potentially Effective Immunochemotherapy for Advanced Natural Killer\/T Cell Lymphoma","volume":"5","author":"Cai","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","article-title":"Sintilimab for Relapsed\/Refractory Extranodal NK\/T Cell Lymphoma: A Multicenter, Single-Arm, Phase 2 Trial (ORIENT-4)","volume":"6","author":"Tao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1182\/bloodadvances.2022009575","article-title":"Treating Relapsed\/Refractory Mature T- and NK-Cell Neoplasms with Tislelizumab: A Multicenter Open-Label Phase 2 Study","volume":"7","author":"Bachy","year":"2023","journal-title":"Blood Adv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1182\/blood-2021-152020","article-title":"Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory\/Relapsed Extranodal Natural Killer\/T Cell Lymphoma, Nasal Type (r\/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase II Trial","volume":"138","author":"Zhang","year":"2021","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2020007247","article-title":"Avelumab for the Treatment of Relapsed or Refractory Extranodal NK\/T-Cell Lymphoma: An Open-Label Phase 2 Study","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.22.02367","article-title":"Sugemalimab Monotherapy for Patients with Relapsed or Refractory Extranodal Natural Killer\/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study","volume":"41","author":"Huang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41392-024-01825-0","article-title":"Sintilimab (Anti-PD-1 Antibody) plus Chidamide (Histone Deacetylase Inhibitor) in Relapsed or Refractory Extranodal Natural Killer T-Cell Lymphoma (SCENT): A Phase Ib\/II Study","volume":"9","author":"Gao","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4143\/crt.2023.1042","article-title":"Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK\/T-Cell Lymphoma in Korea","volume":"56","author":"Lee","year":"2024","journal-title":"Cancer Res. Treat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00277-017-3127-2","article-title":"PD1 Blockade with Low-Dose Nivolumab in NK\/T Cell Lymphoma Failing l-Asparaginase: Efficacy and Safety","volume":"97","author":"Chan","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 Blockade with Pembrolizumab Is Highly Effective in Relapsed or Refractory NK\/T-Cell Lymphoma Failing l-Asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.20892\/j.issn.2095-3941.2020.0400","article-title":"Updating Targets for Natural Killer\/T-Cell Lymphoma Immunotherapy","volume":"18","author":"Xue","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/1097-0215(20010601)92:5<692::AID-IJC1237>3.0.CO;2-Z","article-title":"Expression of HLA Class I, Beta(2)-Microglobulin, TAP1 and IL-10 in Epstein-Barr Virus-Associated Nasal NK\/T-Cell Lymphoma: Implications for Tumor Immune Escape Mechanism","volume":"92","author":"Shen","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2303913","DOI":"10.1002\/advs.202303913","article-title":"Single-cell Analysis Reveals Malignant Cells Reshape the Cellular Landscape and Foster an Immunosuppressive Microenvironment of Extranodal NK\/T-cell Lymphoma","volume":"10","author":"Li","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/blood-2024-211658","article-title":"Unveiling the Tumor Microenvironment in Extranodal NK\/T-Cell Lymphoma (ENKTCL) Patients with in Situ Spatial Transcriptomics","volume":"144","author":"Karagkouni","year":"2024","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zhang, C., Wang, L., Xu, C., Xu, H., and Wu, Y. (2023). Resistance Mechanisms of Immune Checkpoint Inhibition in Lymphoma: Focusing on the Tumor Microenvironment. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1079924"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a Cancer Immunotherapy Target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Luo, Y., Cai, X., Yang, B., Lu, F., Yi, C., and Wu, G. (2024). Advances in Understanding the Role of Immune Checkpoint LAG-3 in Tumor Immunity: A Comprehensive Review. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1402837"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and Its Role in Regulating Anti-Tumor Immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 Comes of Age as an Inhibitory Receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and Cellular Insights into T Cell Exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41419-024-06999-7","article-title":"LMP1 Enhances Aerobic Glycolysis in Natural Killer\/T Cell Lymphoma","volume":"15","author":"Song","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"113626","DOI":"10.1016\/j.isci.2025.113626","article-title":"Single-Cell and Spatial Transcriptomics Reveal Intratumor Heterogeneity and Immune Evasion in Natural Killer\/T Cell Lymphoma","volume":"28","author":"Ma","year":"2025","journal-title":"iScience"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.3324\/haematol.2014.116087","article-title":"Serum Survivin and Vascular Endothelial Growth Factor in Extranodal NK\/T-Cell Lymphoma, Nasal Type: Implications for a Potential New Prognostic Indicator","volume":"100","author":"Kim","year":"2015","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","article-title":"Extracellular Matrix Remodeling in Tumor Progression and Immune Escape: From Mechanisms to Treatments","volume":"22","author":"Yuan","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1182\/blood-2011-05-354142","article-title":"Prospective Measurement of Epstein-Barr Virus\u2013DNA in Plasma and Peripheral Blood Mononuclear Cells of Extranodal NK\/T-Cell Lymphoma, Nasal Type","volume":"118","author":"Suzuki","year":"2011","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"30317","DOI":"10.18632\/oncotarget.4505","article-title":"Post-Treatment Plasma EBV-DNA Positivity Predicts Early Relapse and Poor Prognosis for Patients with Extranodal NK\/T Cell Lymphoma in the Era of Asparaginase","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2012-06-435024","article-title":"Clinical Implications of Plasma Epstein-Barr Virus DNA in Early-Stage Extranodal Nasal-Type NK\/T-Cell Lymphoma Patients Receiving Primary Radiotherapy","volume":"120","author":"Wang","year":"2012","journal-title":"Blood"},{"key":"ref_59","first-page":"2714","article-title":"Dynamic Change in Epstein-Barr Virus DNA Predicts Prognosis in Early Stage Natural Killer\/T-Cell Lymphoma with Pegaspargase-Based Treatment: Long-Term Follow-up and Biomarker Analysis from the NHL-004 Multicenter Randomized Study","volume":"110","author":"Zhong","year":"2025","journal-title":"Haematologica"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/s41375-020-1000-0","article-title":"Whole-Genome Sequencing Identifies Responders to Pembrolizumab in Relapse\/Refractory Natural-Killer\/T Cell Lymphoma","volume":"34","author":"Lim","year":"2020","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Kim, S.J., Ryu, K.J., Park, B., Yoon, S.E., Cho, J., Park, Y., and Kim, W.S. (2022). Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK\/T-Cell Lymphoma. Cancers, 14.","DOI":"10.3390\/cancers14225618"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/10428194.2020.1821011","article-title":"Frequent Mutations in HLA and Related Genes in Extranodal NK\/T Cell Lymphomas","volume":"62","author":"Polprasert","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"103614","DOI":"10.1016\/j.ebiom.2021.103614","article-title":"SLC1A1 Mediated Glutamine Addiction and Contributed to Natural Killer T-Cell Lymphoma Progression with Immunotherapeutic Potential","volume":"72","author":"Xiong","year":"2021","journal-title":"Ebiomedicine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"176","DOI":"10.18632\/genesandcancer.180","article-title":"The Promising Immune Checkpoint LAG-3: From Tumor Microenvironment to Cancer Immunotherapy","volume":"9","author":"Long","year":"2018","journal-title":"Genes. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"100079","DOI":"10.1016\/j.iotech.2022.100079","article-title":"Clinical Landscape of LAG-3-Targeted Therapy","volume":"14","author":"Chocarro","year":"2022","journal-title":"Immuno-Oncol. Technol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for Cancer Immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: Distinct Functions in Immune Regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1038\/s41591-023-02593-0","article-title":"The PD-1- and LAG-3-Targeting Bispecific Molecule Tebotelimab in Solid Tumors and Hematologic Cancers: A Phase 1 Trial","volume":"29","author":"Luke","year":"2023","journal-title":"Nat. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41416-025-02990-x","article-title":"First-in-Human Phase I Study of EMB-02, a Bispecific Antibody Targeting PD-1 and LAG-3 in Patients with Advanced Solid Tumors","volume":"132","author":"Day","year":"2025","journal-title":"Br. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and Antitumour Activity of Cadonilimab, an Anti-PD-1\/CTLA-4 Bispecific Antibody, for Patients with Advanced Solid Tumours (COMPASSION-03): A Multicentre, Open-Label, Phase 1b\/2 Trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Bei, W., Wang, L., Lu, N., Xu, C., Liang, H., Ke, L., Ye, Y., He, S., and Dong, S. (2025). Efficacy and Safety of Cadonilimab (PD-1\/CTLA-4 Bispecific) in Combination with Chemotherapy in Anti-PD-1-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Single-Arm, Open-Label, Phase 2 Trial. BMC Med., 23.","DOI":"10.1186\/s12916-025-03985-4"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-04-2263","article-title":"Enhanced Natural Killer Cell Binding and Activation by Low-Fucose IgG1 Antibody Results in Potent Antibody-Dependent Cellular Cytotoxicity Induction at Lower Antigen Density","volume":"11","author":"Niwa","year":"2005","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00277-015-2359-2","article-title":"CD38 Expression Predicts Poor Prognosis and Might Be a Potential Therapy Target in Extranodal NK\/T Cell Lymphoma, Nasal Type","volume":"94","author":"Wang","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.3109\/10428194.2014.974048","article-title":"Prognostic Implications of CD30 Expression in Extranodal Natural Killer\/T-Cell Lymphoma According to Treatment Modalities","volume":"56","author":"Kim","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40880-017-0212-9","article-title":"CD30 Expression in Extranodal Natural Killer\/T-Cell Lymphoma, Nasal Type among 622 Cases of Mature T-Cell and Natural Killer-Cell Lymphoma at a Single Institution in South China","volume":"36","author":"Feng","year":"2017","journal-title":"Chin. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"16547","DOI":"10.18632\/oncotarget.24044","article-title":"CD30 Expression and Survival in Extranodal NK\/T-Cell Lymphoma: A Systematic Review and Meta-Analysis","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of Daratumumab on Natural Killer Cells and Impact on Clinical Outcomes in Relapsed or Refractory Multiple Myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-Mediated Phagocytosis Contributes to the Anti-Tumor Activity of the Therapeutic Antibody Daratumumab in Lymphoma and Multiple Myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"mAbs"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-020-01020-y","article-title":"Daratumumab Monotherapy for Patients with Relapsed or Refractory Natural Killer\/T-Cell Lymphoma, Nasal Type: An Open-Label, Single-Arm, Multicenter, Phase 2 Study","volume":"14","author":"Huang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00277-023-05603-w","article-title":"Immune Profiling of Patients with Extranodal Natural Killer\/T Cell Lymphoma Treated with Daratumumab","volume":"103","author":"Qing","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e002123","DOI":"10.1136\/jitc-2020-002123","article-title":"Determinants of Response to Daratumumab in Epstein-Barr Virus-Positive Natural Killer and T-Cell Lymphoma","volume":"9","author":"Mustafa","year":"2021","journal-title":"J. ImmunoTher. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Lee, W.W.L., Lim, J.Q., Tang, T.P.L., Tan, D., Koh, S.M., Puan, K.J., Wang, L.W., Lim, J., Tan, K.P., and Chng, W.J. (2024). Counterproductive Effects of Anti-CD38 and Checkpoint Inhibitor for the Treatment of NK\/T Cell Lymphoma. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1346178"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/blood.2024027109","article-title":"Efficacy of Combined CD38 and PD-1 Inhibition with Isatuximab and Cemiplimab for Relapsed\/Refractory NK\/T-Cell Lymphoma","volume":"146","author":"Kim","year":"2025","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3324\/haematol.2021.278301","article-title":"A Phase II Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive and CD30-Positive Lymphomas","volume":"106","author":"Kim","year":"2021","journal-title":"Haematologica"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4143\/crt.2019.198","article-title":"Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial","volume":"52","author":"Kim","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"254","DOI":"10.5045\/br.2015.50.4.254","article-title":"Complete Remission in CD30-Positive Refractory Extranodal NK\/T-Cell Lymphoma with Brentuximab Vedotin","volume":"50","author":"Kim","year":"2015","journal-title":"Blood Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"104944","DOI":"10.1016\/j.critrevonc.2025.104944","article-title":"The Role of CD70 Expression in Lymphoma Pathogenesis, Progression, and Treatment","volume":"216","author":"Zheng","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00280-015-2909-2","article-title":"First-in-Human Multicenter Phase I Study of BMS-936561 (MDX-1203), an Antibody-Drug Conjugate Targeting CD70","volume":"77","author":"Owonikoko","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10637-018-0655-0","article-title":"A Phase 1 Trial of SGN-CD70A in Patients with CD70-Positive Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma","volume":"37","author":"Phillips","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"100770","DOI":"10.1016\/j.tranon.2020.100770","article-title":"Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies against Extranodal Nasal Natural Killer\/T Cell Lymphoma","volume":"13","author":"Zheng","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.3324\/haematol.2016.146977","article-title":"European Phase II Study of Mogamulizumab, an Anti-CCR4 Monoclonal Antibody, in Relapsed\/Refractory Peripheral T-Cell Lymphoma","volume":"101","author":"Zinzani","year":"2016","journal-title":"Haematologica"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A Pilot Study of Alemtuzumab (Anti-CD52 Monoclonal Antibody) Therapy for Patients with Relapsed or Chemotherapy-Refractory Peripheral T-Cell Lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1\u20132 Trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_97","first-page":"372","article-title":"Mechanisms of Resistance to CAR T Cell Therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-023-01483-9","article-title":"Novel Target and Treatment Agents for Natural Killer\/T-Cell Lymphoma","volume":"16","author":"Tian","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Li, H., Song, W., Wu, J., Shi, Z., Gao, Y., Li, J., Han, L., Zhang, J., Li, Z., and Li, Y. (2023). CAR-T Cells Targeting CD38 and LMP1 Exhibit Robust Antitumour Activity against NK\/T Cell Lymphoma. BMC Med., 21.","DOI":"10.1186\/s12916-023-03040-0"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","article-title":"Making Better Chimeric Antigen Receptors for Adoptive T-Cell Therapy","volume":"22","author":"Maus","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Yang, J., Li, P., Piao, Y., Liu, X., Wei, L., Sang, W., Zhang, L., and Wang, L. (2022). CD56-Negative Extranodal Natural Killer\/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy with or without Asparaginase. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.829366"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","article-title":"The Immunology of Epstein-Barr Virus-Induced Disease","volume":"33","author":"Taylor","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Shannon-Lowe, C., and Rickinson, A. (2019). The Global Landscape of EBV-Associated Tumors. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00713"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1093\/emboj\/18.11.3064","article-title":"Latent Membrane Protein 1 of Epstein-Barr Virus Interacts with JAK3 and Activates STAT Proteins","volume":"18","author":"Gires","year":"1999","journal-title":"EMBO J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T Cell Therapy: Current Limitations and Potential Strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1746-1596-6-79","article-title":"Aberrant Antigenic Expression in Extranodal NK\/T-Cell Lymphoma: A Multi-Parameter Study from Thailand","volume":"6","author":"Pongpruttipan","year":"2011","journal-title":"Diagn. Pathol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/hon.2482","article-title":"Frequent Expression of CD30 in Extranodal NK\/T-Cell Lymphoma: Potential Therapeutic Target for Anti-CD30 Antibody-Based Therapy","volume":"36","author":"Kawamoto","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision Tumor Recognition by T Cells with Combinatorial Antigen-Sensing Circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering Strategies to Overcome the Current Roadblocks in CAR T Cell Therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","article-title":"CD19-Specific CAR T Cells That Express a PD-1\/CD28 Chimeric Switch-Receptor Are Effective in Patients with PD-L1\u2013Positive B-Cell Lymphoma","volume":"27","author":"Liu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained Complete Responses in Patients with Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjh.13051","article-title":"Establishment and Operation of a Good Manufacturing Practice-Compliant Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic Cell Bank for the Treatment of EBV-Associated Lymphoproliferative Disease","volume":"167","author":"Vickers","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s00277-021-04558-0","article-title":"Autologous EBV-Specific T Cell Treatment Results in Sustained Responses in Patients with Advanced Extranodal NK\/T Lymphoma: Results of a Multicenter Study","volume":"100","author":"Kim","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-Term Outcome of EBV-Specific T-Cell Infusions to Prevent or Treat EBV-Related Lymphoproliferative Disease in Transplant Recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","article-title":"Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus\u2013Induced Lymphoma in Allogeneic Transplant Recipients","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Nair, S., and Dhodapkar, M.V. (2017). Natural Killer T Cells in Cancer Immunotherapy. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01178"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nature05907","article-title":"CD1d-Lipid-Antigen Recognition by the Semi-Invariant NKT T-Cell Receptor","volume":"448","author":"Borg","year":"2007","journal-title":"Nature"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/2326-6066.CIR-15-0098","article-title":"NKG2D Receptor and Its Ligands in Host Defense","volume":"3","author":"Lanier","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12935-023-02923-9","article-title":"CAR-NKT Cell Therapy: A New Promising Paradigm of Cancer Immunotherapy","volume":"23","author":"Hadiloo","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Niedzielska, M., Chalmers, A., Popis, M.C., Altman-Sharoni, E., Addis, S., Beulen, R., Rudqvist, N.-P., Chantzoura, E., Purbhoo, M.A., and Chand, D. (2025). CAR-iNKT Cells: Redefining the Frontiers of Cellular Immunotherapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1625426"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT Cells in Relapsed or Refractory Neuroblastoma: Updated Phase 1 Trial Interim Results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41568-019-0153-5","article-title":"\u0393\u03b4 T Cells: Pleiotropic Immune Effectors with Therapeutic Potential in Cancer","volume":"19","author":"Mensurado","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41423-020-0504-x","article-title":"Cancer Immunotherapy with \u0393\u03b4 T Cells: Many Paths Ahead of Us","volume":"17","author":"Kabelitz","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-Best: Unique Contributions of \u0393\u03b4 T Cells to Immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e27572","DOI":"10.4161\/onci.27572","article-title":"\u0393\u03b4 T Cells for Cancer Immunotherapy: A Systematic Review of Clinical Trials","volume":"3","author":"Fisher","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_127","first-page":"260","article-title":"Preclinical Characterization of ISB 1342, a CD38 \u00d7 CD3 T-Cell Engager for Relapsed\/Refractory Multiple Myeloma","volume":"142","author":"Pouleau","year":"2023","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"TPS7070","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7070","article-title":"A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with CD38 Expressing Relapsed\/Refractory Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia","volume":"40","author":"Kearl","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"100671","DOI":"10.1016\/j.medj.2025.100671","article-title":"CD70-Targeted Cancer Theranostics: Progress and challengesCD70","volume":"6","author":"Wei","year":"2025","journal-title":"Med"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","article-title":"CD16xCD33 Bispecific Killer Cell Engager (BiKE) Activates NK Cells against Primary MDS and MDSC CD33+ Targets","volume":"123","author":"Gleason","year":"2014","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Zhang, M., Lam, K.-P., and Xu, S. (2023). Natural Killer Cell Engagers (NKCEs): A New Frontier in Cancer Immunotherapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1207276"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A Phase 1 Study of the Bispecific Anti-CD30\/CD16A Antibody Construct AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","article-title":"Combining AFM13, a Bispecific CD30\/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses against CD30+ Malignancies","volume":"27","author":"Kerbauy","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","article-title":"Allogeneic NK Cells with a Bispecific Innate Cell Engager in Refractory Relapsed Lymphoma: A Phase\u20091 Trial","volume":"31","author":"Nieto","year":"2025","journal-title":"Nat. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant Gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein-Barr Virus Vaccine in Healthy Young Adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41541-022-00587-6","article-title":"Urgency and Necessity of Epstein-Barr Virus Prophylactic Vaccines","volume":"7","author":"Zhong","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"100658","DOI":"10.1016\/j.xcrm.2022.100658","article-title":"Immunization with a Self-Assembling Nanoparticle Vaccine Displaying EBV gH\/gL Protects Humanized Mice against Lethal Viral Challenge","volume":"3","author":"Malhi","year":"2022","journal-title":"Cell Rep. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1128\/JVI.78.2.768-778.2004","article-title":"Dual Stimulation of Epstein-Barr Virus (EBV)-Specific CD4+- and CD8+-T-Cell Responses by a Chimeric Antigen Construct: Potential Therapeutic Vaccine for EBV-Positive Nasopharyngeal Carcinoma","volume":"78","author":"Taylor","year":"2004","journal-title":"J. Virol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"19255","DOI":"10.18632\/oncotarget.13770","article-title":"Novel Epstein-Barr Virus-like Particles Incorporating gH\/gL-EBNA1 or gB-LMP2 Induce High Neutralizing Antibody Titers and EBV-Specific T-Cell Responses in Immunized Mice","volume":"8","author":"Perez","year":"2017","journal-title":"Oncotarget"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood-2017-12-791418","article-title":"Advances in the Treatment of Extranodal NK\/T-Cell Lymphoma, Nasal Type","volume":"131","author":"Yamaguchi","year":"2018","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic Cell Death in Cancer Therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semradonc.2014.07.005","article-title":"Radiotherapy and Immunogenic Cell Death","volume":"25","author":"Golden","year":"2015","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40425-018-0361-7","article-title":"Radiation Therapy and PD-1\/PD-L1 Blockade: The Clinical Development of an Evolving Anticancer Combination","volume":"6","author":"Gong","year":"2018","journal-title":"J. ImmunoTher. Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.18632\/oncotarget.2608","article-title":"EBV-Driven LMP1 and IFN-\u03b3 up-Regulate PD-L1 in Nasopharyngeal Carcinoma: Implications for Oncotargeted Therapy","volume":"5","author":"Fang","year":"2014","journal-title":"Oncotarget"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2217\/fon-2023-0065","article-title":"Tislelizumab and Radiation Therapy in Low-Risk Early-Stage Extranodal Natural Killer\/T-Cell Lymphoma, Nasal Type: A Phase II Study Protocol","volume":"20","author":"Li","year":"2024","journal-title":"Future Oncol."},{"key":"ref_150","unstructured":"Liu, C. (2026, April 21). Tislelizumab in Combination with Gemcitabine, Pegaspargas, and Etoposide (Ppge) in Patients with Primary Nk\/T-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Study. Available online: https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/420199\/."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"104420","DOI":"10.1016\/j.ebiom.2022.104420","article-title":"Histone Deacetylases Inhibitor Chidamide Synergizes with Humanized PD1 Antibody to Enhance T-Cell Chemokine Expression and Augment Ifn-\u03b3 Response in NK-T Cell Lymphoma","volume":"87","author":"Wen","year":"2023","journal-title":"Ebiomedicine"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"10903","DOI":"10.2147\/OTT.S217767","article-title":"DNA Methyltransferase Inhibitors: Catalysts for Antitumour Immune Responses","volume":"12","author":"Dan","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1158\/2159-8290.CD-25-0587","article-title":"Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed\/Refractory NK\/T-Cell Lymphoma","volume":"15","author":"Huang","year":"2025","journal-title":"Cancer Discov."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10565-025-09994-6","article-title":"CPT1A Mediates Succinylation of LDHA at K318 Site Promoteing Metabolic Reprogramming in NK\/T-Cell Lymphoma Nasal Type","volume":"41","author":"Tian","year":"2025","journal-title":"Cell Biol. Toxicol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"102006","DOI":"10.1016\/j.tranon.2024.102006","article-title":"Succinylation of 14-3-3 Theta by CPT1A Promotes Survival and Paclitaxel Resistance in Nasal Type Extranodal Natural Killer\/T-Cell Lymphoma","volume":"46","author":"Cui","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Yang, T., You, C., Meng, S., Lai, Z., Ai, W., and Zhang, J. (2022). EBV Infection and Its Regulated Metabolic Reprogramming in Nasopharyngeal Tumorigenesis. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.935205"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1777625","DOI":"10.1080\/2162402X.2020.1777625","article-title":"Trial Watch: IDO Inhibitors in Cancer Therapy","volume":"9","author":"Galluzzi","year":"2020","journal-title":"Oncoimmunology"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/9\/1358\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:13:40Z","timestamp":1778213620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/9\/1358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":157,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18091358"],"URL":"https:\/\/doi.org\/10.3390\/cancers18091358","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}